A 2026 medRxiv preprint using parent-cocreated sensory-related outcome measures found that 83% of children and teens improved on at least 1 PROMIS domain during 6 months of bumetanide treatment.1 The result is interesting, but the unmasked single-case design means the strongest claim is about sensitive outcome tracking, not definitive bumetanide efficacy. Research Highlights Most participants …
A 166-child resting-state fMRI study found that clinician-observed autism severity, not ADHD severity, tracked connectivity strength between a left middle frontal gyrus node and the posterior cingulate/default mode network across children diagnosed with autism or ADHD without autism. The result is transdiagnostic, but asymmetrical: autism traits carried the connectome signal after ADHD ratings were controlled.1 …
A 2026 real-world study involving 1,174 children with epilepsy proposed a levetiracetam therapeutic drug monitoring range of 2.82-24.37 mcg/mL, much lower than commonly cited adult-style ranges, but the same data also warned against treating a drug level as a stand-alone seizure-control predictor. Research Highlights Lower pediatric range: Sun et al. proposed an observational levetiracetam range …
A 2026 study of 958 adults entering Japanese multidisciplinary pain centers found that 17.1% screened positive for ADHD, rising to 27.4% among patients whose average pain was NRS 9-10; ASD screening was 4.4% overall and did not show the same pain-intensity signal.1 Research Highlights ADHD screening was elevated in tertiary pain care: 164 of 958 …
A 2026 ALSPAC analysis tested a narrow claim behind routine genetic screening for childhood attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD): whether rare copy number variants (CNVs; deleted or duplicated DNA segments) make young-adult outcomes worse than ADHD/ASD status alone would predict. In 8,414 people with usable CNV data, ADHD and ASD predicted worse …
A 2026 case report linked 1 mg nightly guanfacine modified-release to first-ever cessation of intrusive deliberate self-harm thoughts in a 16-year-old with attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD) traits, borderline personality disorder (BPD) traits, and post-traumatic stress disorder (PTSD). The same case became more interesting after the patient stopped taking guanfacine and the self-harm …
A 2026 double-blind randomized controlled trial by Kappes et al. in Psychopharmacology found something the smart-drug users likely wouldn’t have predicted: a single 30 mg dose of methylphenidate reduced dishonest misreporting on a die-rolling task from ~22% of trials in the placebo arm to ~6% (in the methylphenidate arm).1 Atomoxetine, a noradrenergic comparator, had no …